Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
Sponsor: Perceive Biotherapeutics, Inc.
Summary
The Phase 1 safety study of VOY-101 is comprised of escalating dose Cohorts, followed by a Phase 2 at the recommended phase 2 dose.
Official title: Phase 1/2a Study of VOY-101 in Subjects With Advanced Non-Neovascular Age-Related Macular Degeneration (JOURNEY)
Key Details
Gender
All
Age Range
60 Years - Any
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2023-06-21
Completion Date
2028-06
Last Updated
2026-08-17
Healthy Volunteers
No
Conditions
Interventions
VOY-101
VOY-101
Locations (16)
Retina Macula Institute of AZ
Scottsdale, Arizona, United States
Retina Consultants San Diego
Poway, California, United States
Retinal Consultants Medical Group
Sacramento, California, United States
Ophthalmic Consultants of Boston
Boston, Massachusetts, United States
The Retina Institute
St Louis, Missouri, United States
Mid Atlantic Retina
Cherry Hill, New Jersey, United States
Retina Northwest
Portland, Oregon, United States
Black Hills Regional Eye Institute
Rapid City, South Dakota, United States
Austin Research Center for Retina
Austin, Texas, United States
Star Retina
Fort Worth, Texas, United States
Retina Center of Texas
Southlake, Texas, United States
University of Utah John A. Moran Eye Center
Salt Lake City, Utah, United States
Sydney Retina Clinic and Day Surgery
Sydney, New South Wales, Australia
Cerulea Clinical Trials
East Melbourne, Victoria, Australia
Rambam Medical Center
Haifa, Israel
Tel-Aviv Sourasky Medical Center, Ophthalmology Division
Tel Aviv, Israel